HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Heart 2008;94:1102-1104; doi:10.1136/hrt.2008.149898
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lindsay, A.
PubMed
Right arrow Articles by Lindsay, A.

JournalScan

Alistair Lindsay, Editor

The first 150 words of the full text of this article appear below.


*   INTERVENTIONAL CARDIOLOGY
 
MULTISTRATEGY: tirofiban and sirolimus in primary PCI
In patients undergoing primary percutaneous coronary intervention, the use of abciximab has been shown to improve ST-segment resolution and to reduce mortality in comparison with placebo. Subsequently, the TARGET (Do Tirofiban and Reo-Pro Give Similar Efficacy) trial, a head-to-head comparison of abciximab against tirofiban, suggested that the former was the more effective of the two drugs, but it was noted that the bolus dose of tirofiban used in the trial was low (10 µg/kg). Therefore the MULTISTRATEGY trial was primarily designed to compare the efficacy of the two drugs when using a more appropriate dose of tirofiban. In addition, as patients with ST-segment elevation myocardial infarction (STEMI) are thought to be at a higher risk for stent thrombosis, patients underwent a second randomisation to either a sirolimus-eluting or non-drug-eluting stent.

An open-label, 2x2 factorial study of 745 patients with STEMI was performed across 16 centres in Italy, Spain . . . [Full text of this article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society